相关实验视频

Updated: Jul 12, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

限制阶段初级骨扩散大B细胞淋巴瘤在Rituximab时代的结果:一个多中心的,回顾性研究

Alexandra Rezazadeh¹, Aniko Szabo¹, Arushi Khurana²

¹Medical College of Wisconsin.

|October 19, 2023

概括

基于rituximab的化疗免疫疗法 (CIT) 后的强化放射治疗 (RT) 并没有改善有限阶段初级骨扩散大B细胞淋巴瘤的结果. 然而,RT可能有利于CIT后部分反应的患者.

科学领域:

在瘤学瘤学.
血液学血液学血液学
辐射瘤学辐射瘤学

背景情况:

初级骨扩散大B细胞淋巴瘤 (DLBCL) 是一种罕见的外节非霍奇金淋巴瘤.
从历史上看,治疗包括化疗,然后是放射治疗 (RT).
在基于Rituximab的现代化疗免疫疗法 (CIT) 后RT的作用对于有限阶段的疾病尚不清楚.

研究的目的:

评估基于rituximab的CIT后的整合性RT在患有I-II阶段原发性骨DLBCL的患者中所带来的益处.
确定RT是否能改善整体存活率 (OS) 和无复发存活率 (RFS).

主要方法:

在2005年至2019年期间,对112名患有I-II期原发性骨DLBCL的患者进行了多中心回顾性分析.
与RT (n=78) 和单独CIT (n=34) 接受CIT的患者之间的结局比较.

主要成果:

在RT和没有RT组之间,10年OS (77.9% vs. 89.0%,P=0.42) 或10年RFS (73.5% vs. 80.3%,P=0.88) 没有显著差异.
亚组分析表明,对于在CIT后仅获得部分反应的患者,RT对RT的潜在益处.

结论:

整合性RT似乎没有改善大多数患者的生存结果,受限阶段原发性骨DLBCL患者接受了基于rituximab的CIT治疗.
对于一组精选的患者来说,RT可能是一个有益的整合选择,这些患者在化疗免疫治疗后获得了部分反应.

更多相关视频

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

相关概念视频

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...